canagliflozin

Today’s podcast is the third in the series of five episodes of “From The Heart - Tying the threads through the evolving body of evidence in HF “. Today's episode is focused on a new class of drugs in heart failure - The Sodium Glucose Like Transporter 2 inhibitors or as they are more commonly known as SGLT2is

For those who have just tuned in to our podcast series for the first time, please do listen into our first episode where we discussed about the basics of heart failure and a brief historical view of heart failure therapies (Link https://www.buzzsprout.com/1947788/10351733-from-the-heart-ep-1-introduction-to-heart-failure-and-a-brief-overview-of-evolving-hf-treatments.mp3?download=true)

The second episode discussed about Entresto, its mechanism of action and clinical evidence in heart failure. (Link https://www.buzzsprout.com/1947788/10498068-from-the-heart-ep-2-entresto-the-first-arni-approved-for-heart-failure.mp3?download=true)

Manal Abdelmalek, Ian Rowe and first-timer Ken Cusi join Louise Campbell and Roger Green to review a thought-provoking, assumption-challenging Day Three of #ILC2021.

Most of the presentations the panel covered focused on medications, the core ideas and discussions spoke to changes in thinking. One theme that ran through the discussion was about multi-disciplinary care...and not only because Fatty Liver Endocrinologist Ken Cusi was on the panel. Another was to think about drugs for NASH holistically. In all, this podcast takes the broad view and the long view on treating Fatty Liver diseases, and should provoke new thoughts and ideas in you the listener.